NCI-2022-02710

10551 A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination with Olaparib in Patients with BRCA1/2-Mutant Tumors

This research study is studying a new type of cancer treatment. The treatment combines two drugs - Magrolimab: This is a drug that helps the immune system recognize and attack cancer cells. Olaparib: This is a drug that blocks the PARP enzyme, which helps cancer cells repair their DNA. By blocking PARP, olaparib can make cancer cells more likely to die. This study is testing this combination of drugs in patients with tumors that have mutations in the BRCA1 or BRCA2 genes. These genes are involved in DNA repair, so tumors with mutations in these genes are often more sensitive to drugs that block PARP.The trial is still in the early stages (Phase I/II), so the main goals are to find the safest dose of the drugs and to see if they are effective in treating cancer. If the trial is successful, it could lead to larger studies that test the drugs in more patients.

Early stages: Early phase (phases I and II) studies help researchers determine: Whether a new treatment is safe, what its side effects are and the best dose of the new treatment.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05807126

NCI-2022-02710

Clinical Trial Site: Einstein

To see all available clinical trials click here.